Antipsychotic Drugs

Correct Answer

B — Haloperidol

Rationale

Haloperidol is a first-generation (typical) antipsychotic — a high-potency agent that produces its antipsychotic effect through potent, relatively selective dopamine D2 receptor blockade. Aripiprazole is a partial D2 agonist (third mechanistic category). Clozapine and quetiapine are both second-generation (atypical) antipsychotics, defined by their combination of D2 and serotonin 5-HT2A receptor blockade.

Correct Answer

D — Aripiprazole

Rationale

Aripiprazole is classified as a partial D2 agonist — a mechanistically distinct third category of antipsychotic that partially activates the D2 receptor rather than blocking it completely. Haloperidol is a first-generation (typical) antipsychotic. Clozapine and olanzapine are both second-generation (atypical) antipsychotics, defined by combined D2 and serotonin 5-HT2A receptor blockade.

Correct Answer

A — Chlorpromazine

Rationale

Chlorpromazine is classified as a low-potency first-generation antipsychotic, requiring doses of 200 to 1000 milligrams per day to achieve therapeutic dopamine D2 receptor occupancy. Haloperidol, fluphenazine, and perphenazine are all classified as high-potency first-generation antipsychotics, achieving equivalent D2 blockade at doses of 2 to 20 milligrams per day. Potency in this context refers to the milligram dose required, not to clinical superiority.

Correct Answer

C — Clozapine

Rationale

Clozapine is classified as a second-generation (atypical) antipsychotic, a category defined pharmacologically by the combination of dopamine D2 receptor blockade with serotonin 5-HT2A receptor blockade. Haloperidol and fluphenazine are both first-generation (typical) antipsychotics. Aripiprazole belongs to the third mechanistic category — the partial D2 agonists — and is classified separately from both first- and second-generation agents.

Correct Answer

B — Fluphenazine

Rationale

Fluphenazine is classified as a high-potency first-generation antipsychotic, achieving therapeutic dopamine D2 receptor occupancy at doses of 2 to 20 milligrams per day. Chlorpromazine and thioridazine are both low-potency first-generation antipsychotics, requiring doses of 200 to 1000 milligrams per day. Quetiapine is a second-generation (atypical) antipsychotic and does not belong to the first-generation potency classification system.

Correct Answer

A — Olanzapine and quetiapine

Rationale

Olanzapine and quetiapine are both classified as second-generation (atypical) antipsychotics, a category defined by the combination of dopamine D2 and serotonin 5-HT2A receptor blockade. Haloperidol, fluphenazine, and chlorpromazine are all first-generation (typical) antipsychotics. Aripiprazole and cariprazine are both partial D2 agonists — a mechanistically distinct third category that is classified separately from both first- and second-generation agents.

Correct Answer

C — D2 blockade in the mesolimbic pathway reduces dopamine overactivity that drives positive symptoms

Rationale

The mesolimbic pathway projects from the ventral tegmental area to the nucleus accumbens and limbic structures. In schizophrenia, this pathway is overactive — excess dopamine signaling in this circuit produces the positive symptoms of the illness, including hallucinations and delusions. Blocking D2 receptors here reduces that overactivity and suppresses positive symptoms, which is the primary therapeutic mechanism of all antipsychotics. The nigrostriatal pathway governs motor control; D2 blockade there produces extrapyramidal side effects, not therapeutic benefit. The tuberoinfundibular pathway regulates prolactin; D2 blockade there elevates prolactin, not dopamine. The mesocortical pathway is already dopamine-deficient in schizophrenia; D2 blockade there worsens negative symptoms rather than correcting them.

Correct Answer

A — D2 receptor blockade in the nigrostriatal pathway disrupts dopamine-mediated motor control

Rationale

The nigrostriatal pathway projects from the substantia nigra pars compacta to the striatum and is the dopamine circuit responsible for motor control — the same pathway that degenerates in Parkinson disease. When antipsychotics block D2 receptors in this pathway, they pharmacologically recreate dopamine deficiency in the motor system, producing a cluster of drug-induced motor syndromes collectively called extrapyramidal symptoms (acute dystonia, akathisia, drug-induced parkinsonism, and tardive dyskinesia). Mesolimbic D2 blockade reduces positive symptoms. Tuberoinfundibular D2 blockade elevates prolactin. Mesocortical D2 blockade can worsen negative symptoms and cognitive function — not motor function.

Correct Answer

D — D2 blockade in the tuberoinfundibular pathway removes tonic dopamine inhibition of prolactin release

Rationale

The tuberoinfundibular pathway projects from the hypothalamic arcuate nucleus to the anterior pituitary via the portal circulation. Under normal conditions, dopamine released by this pathway activates D2 receptors on pituitary lactotroph cells, tonically suppressing prolactin secretion. When antipsychotics block these D2 receptors, this inhibitory signal is removed, and prolactin is released without restraint — producing hyperprolactinemia and its clinical consequences (galactorrhea, amenorrhea, sexual dysfunction, and reduced bone density over time). This mechanism is specific to the tuberoinfundibular pathway and is unrelated to the mesolimbic, nigrostriatal, or mesocortical circuits.

Correct Answer

B — D2 blockade in the mesocortical pathway further reduces dopamine activity in a pathway that is already deficient

Rationale

The mesocortical pathway projects from the ventral tegmental area to the prefrontal cortex and is responsible for working memory, executive function, and the motivational and affective capacities that are impaired in negative symptoms. In schizophrenia, this pathway already has insufficient dopamine activity — mesocortical hypoactivity is the neurobiological substrate of negative symptoms. When antipsychotics block D2 receptors in this already-deficient pathway, they reduce dopamine signaling further, worsening the very deficits the treatment cannot address. This is why negative symptoms respond poorly to standard antipsychotics and may actually worsen, especially with first-generation agents that have no mechanisms to partially spare the mesocortical pathway.

Correct Answer

A — Blockade of serotonin 5-HT2A receptors partially restores dopamine release in the nigrostriatal pathway, offsetting the motor consequences of D2 blockade

Rationale

Second-generation antipsychotics combine D2 receptor blockade with blockade of serotonin 5-HT2A receptors. Serotonin normally suppresses dopamine release in the striatum through inhibitory interneurons. When an antipsychotic also blocks 5-HT2A receptors, this inhibitory serotonin signal is removed, and dopamine release in the nigrostriatal pathway is partially restored — which partially counteracts the motor side effects that would otherwise result from D2 blockade alone. The higher the ratio of 5-HT2A blockade to D2 blockade, the lower the extrapyramidal symptom burden; this is the pharmacological definition of atypicality. Second-generation antipsychotics do not achieve selective mesolimbic D2 blockade — they block D2 receptors throughout the brain, just as first-generation agents do. Their reduced motor burden comes from the 5-HT2A interaction, not from pathway selectivity.

Correct Answer

C — Blockade of histamine H1 receptors in the central nervous system produces sedation and stimulates appetite through hypothalamic effects

Rationale

Histamine H1 receptor blockade in the central nervous system produces two clinically important effects: sedation and drowsiness (through loss of histamine's arousal-promoting action), and appetite stimulation through hypothalamic mechanisms that are a major driver of the weight gain seen with high-H1-affinity antipsychotics. The agents with the highest H1 affinity — clozapine, olanzapine, and quetiapine — carry the greatest risk for both sedation and weight gain. Each of the other receptor interactions listed produces its own distinct clinical effect: dopamine D2 blockade in the mesolimbic pathway underlies antipsychotic efficacy for positive symptoms; muscarinic M1 blockade produces anticholinergic effects such as dry mouth, urinary retention, and constipation; and alpha-1 adrenergic blockade produces orthostatic hypotension. Recognizing which receptor produces which clinical consequence is the key organizing principle for predicting antipsychotic adverse effect profiles.

Correct Answer

B — Blockade of muscarinic M1 receptors at peripheral cholinergic synapses

Rationale

Dry mouth, urinary retention, and constipation are classic anticholinergic effects produced by blockade of muscarinic M1 receptors at peripheral cholinergic synapses. Muscarinic receptors normally mediate parasympathetic tone — stimulating salivation, promoting bladder contraction, and driving gastrointestinal motility. Blocking these receptors produces the opposite: decreased saliva (dry mouth), impaired bladder emptying (urinary retention), and slowed gut movement (constipation). Clozapine has among the highest muscarinic M1 receptor affinity of any antipsychotic, making anticholinergic effects prominent with this agent. H1 blockade causes sedation and weight gain. Alpha-1 blockade causes orthostatic hypotension. Tuberoinfundibular D2 blockade elevates prolactin.

Correct Answer

D — Positive symptoms — because antipsychotics block mesolimbic dopamine excess that drives hallucinations and delusions

Rationale

Positive symptoms — hallucinations, delusions, and disorganized thinking — are the dimension of schizophrenia most responsive to antipsychotic treatment. This responsiveness has a direct neurobiological explanation: positive symptoms are driven by mesolimbic dopamine excess, and all antipsychotics reduce this excess by blocking D2 receptors in the mesolimbic pathway. Most patients achieve substantial reduction in positive symptoms with adequate antipsychotic therapy. Negative symptoms (blunted affect, avolition, anhedonia) arise from mesocortical dopamine deficiency — antipsychotics cannot correct this deficiency and may worsen it through additional mesocortical D2 blockade. Cognitive symptoms have no currently approved pharmacological treatment; antipsychotics do not robustly improve cognitive function. No antipsychotic directly enhances prefrontal D1 receptor signaling.

Correct Answer

C — Combined blockade of dopamine D2 and serotonin 5-HT2A receptors, which partially restores dopamine release in the nigrostriatal pathway

Rationale

The physician is selecting a second-generation (atypical) antipsychotic. The pharmacological basis of the reduced motor side effect burden in this drug class is the combined blockade of dopamine D2 receptors and serotonin 5-HT2A receptors. Serotonin normally suppresses dopamine release in the striatum; when 5-HT2A receptors are blocked alongside D2 receptors, this suppression is removed and dopamine tone in the nigrostriatal pathway is partially restored. This partial restoration counteracts the extrapyramidal consequences that D2 blockade alone would otherwise produce. Second-generation antipsychotics do not selectively block mesolimbic D2 receptors — they block D2 receptors throughout the brain, including the nigrostriatal pathway, just as first-generation agents do. The reduced motor burden comes from the serotonin interaction, not from pathway selectivity. Partial D2 agonism is the mechanism of a separate third category — the partial agonists such as aripiprazole — not of the second-generation class.

Correct Answer

A — Dopamine D2 blockade in the mesocortical pathway further reduces dopamine activity in a circuit that is already deficient in schizophrenia

Rationale

Blunted affect, avolition, and social withdrawal are negative symptoms of schizophrenia. These symptoms arise from dopamine deficiency in the mesocortical pathway — the circuit projecting from the ventral tegmental area to the prefrontal cortex. Because this pathway is already underactive in schizophrenia, adding dopamine D2 blockade with haloperidol reduces an already-insufficient dopamine signal further, worsening the very symptoms it cannot treat. This pharmacological limitation explains why negative symptoms respond poorly to first-generation antipsychotics and may actually worsen with them. The mesolimbic pathway is the site of dopamine excess in schizophrenia; D2 blockade there reduces positive symptoms, which did improve in this patient. H1 and M1 receptor interactions produce sedation and anticholinergic effects respectively, which are distinct adverse effects — not the mechanism underlying worsening of primary negative symptoms.

Correct Answer

D — Blockade of dopamine D2 receptors in the tuberoinfundibular pathway removes the tonic inhibition of prolactin release from pituitary lactotroph cells

Rationale

The tuberoinfundibular pathway projects from the hypothalamic arcuate nucleus to the anterior pituitary, where dopamine acts on D2 receptors to tonically suppress prolactin secretion from lactotroph cells. Risperidone — and antipsychotics as a class — blocks these D2 receptors, removing the inhibitory brake on prolactin release. The resulting elevation in prolactin (hyperprolactinemia) produces galactorrhea (inappropriate milk secretion) and menstrual irregularities including amenorrhea. Risperidone is associated with the highest rate of hyperprolactinemia among second-generation antipsychotics. Serotonin 5-HT2A blockade reduces extrapyramidal symptoms through a nigrostriatal mechanism and does not directly stimulate prolactin. Histamine H1 blockade produces sedation and weight gain, not hormonal effects.

Correct Answer

B — Blockade of alpha-1 adrenergic receptors on vascular smooth muscle impairs the vasoconstriction response needed to maintain blood pressure when standing

Rationale

When a person stands, gravity causes blood to pool in the lower extremities. The normal compensatory response is sympathetically mediated vasoconstriction through alpha-1 adrenergic receptors on vascular smooth muscle, which maintains blood pressure and cerebral perfusion. Chlorpromazine blocks these alpha-1 receptors, impairing this vasoconstriction response and allowing blood pressure to fall upon standing — producing orthostatic hypotension with dizziness and near-syncope. Low-potency first-generation antipsychotics such as chlorpromazine carry the highest alpha-1 adrenergic blockade burden of any antipsychotic class, making orthostatic hypotension a prominent adverse effect. Clozapine and other agents with high alpha-1 affinity carry similar risk. Nigrostriatal D2 blockade produces motor syndromes, not postural hypotension. H1 blockade produces sedation and weight gain. Muscarinic M1 blockade at cardiac synapses would be expected to increase heart rate, but it is not the mechanism of the blood pressure drop on standing.